Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored Alzheimer's care cuts hospital visits, study finds

NCT ID NCT04820127

Symptom relief Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a personalized approach to manage agitation in people with Alzheimer's disease living at home. A nurse worked with doctors and caregivers to create a custom care plan, using video calls and training. The goal was to reduce hospitalizations and ease caregiver stress. 668 patients and their caregivers took part over 18 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

668 people

The number who actually took part.

Started

Oct 2021

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the patient : * Diagnosed with major neuro-cognitive disorders (DSM V) at all severity stages. * Leaving at home * Assisted by a caregiver, from patient's family or personal environment, assuming most of patient care (spending at least 6 hours per week with the patient) * caregiver available to come with the patient to study visits as planned per protocol * existing agitation since at least one month (according to International Psychogeriatric Association (IPA) criteria) * agitation severity ≥ 2 , based on Clinician Global Impression of Severity (CGI-S) (at least mild severity) * the patient, his/her family member/trusted person , or his /her legal responsible has provided written informed consent to participate in the study * referring physician's oral approval obtained for patient participation in the study * Affiliated to French Healthcare System For the caregiver: * Has provided his/her written informed consent to participate in the study * Ability to understand and speak French properly, ability to complete the questionnaires and assess the patient. * Affiliated to French Healthcare System Exclusion Criteria: For the patient: * Agitation symptoms attributable either to other concomitant prescriptions, or to other psychiatric or evolving somatic diseases. * Patient living in a residential care facility or having an institutionalization project within 6 months * Patient with clinically significant or unstable disease that could affect he/her ability to come for the study visit or complete the evaluations planned as per protocol * Concomitant participation to any other interventional research study * Patient under legal protection. For the caregiver: * Caregiver under legal protection. * Limited internet access or caregiver feeling unable to use it

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease

Contacts and locations

Locations

  • CH Lannemezan

    Lannemezan, France

  • CH Lavaur

    Lavaur, France

  • CH Montauban

    Montauban, France

  • CH d'Albi

    Albi, France

  • CH de Bigorre

    Vic-en-Bigorre, France

  • CH de Cahors

    Cahors, France

  • CHI Castres Mazamet

    Castres, France

  • CHI Val d'Ariège

    Saint-Girons, France

  • Carcassonne Hospital

    Carcassonne, 11000, France

  • HNO-Franche-sur-Soâne

    Villefranche-sur-Saône, France

  • Limoges university hospital

    Limoges, France

  • Lyon University Hospital

    Lyon, France

  • Perpignan Hospital

    Perpignan, France

  • Toulouse University Hospital (CHU de Toulouse)

    Toulouse, 31059, France

  • University Hospital Toulouse - Neurology department

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.